Role of Oxidative Stress and Associated Alteration in Enzyme Activities in Obesity Comorbidities
DOI:
https://doi.org/10.17140/OROJ-4-131Keywords:
Obesity; Oxidative stress; Insulin resistance.Abstract
Obesity is defined as having a body mass index (BMI) of 30 kg/m2
or above, with progressively increasing prevalence all over the world in recent years. Obesity is characterized by
deposition of abnormally increased body fat, resulting from increased energy intake relative
to energy expenditure. The condition is associated with several comorbidities that upsurge risk
of morbidity. The purpose of this review is to describe the role of oxidative stress in release of
pro-inflammatory mediators that influence fat and glucose metabolism and is associated with
altered enzyme activity, which results in insulin resistance and other associated comorbidities.
The main pathology is through intensified generation of reactive oxygen species (ROS) and
diminution of antioxidant defense, creating a chronic inflammatory situation that is critically
important in development of comorbidities. New strategies to combat resultant comorbidities
concentrate on weight reduction either solely or coupled with moderately regular exercise. This
policy may be sufficient to improve insulin sensitivity, regulate fatty acid metabolism together
with refining antioxidant defense of the body. Other approaches encourage modulation of dietary pattern through dietary supplements as vitamins, with or without pharmaceutical antioxidants, which may provide a potential therapeutics approach in obesity comorbidities
References
Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin. 2004; 20(3): 295-304. doi: 10.1185/030079903125003008
Keaney JF, Larson MG, Vasan RS, et al. Obesity and sys-temic oxidative stress: Clinical correlates of oxidative stress in the Framingham study. Arterioscler Tromb Vasc Biol. 2003; 23: 434-439. doi: 10.1161/01.ATV.0000058402.34138.11
Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010; 2010, pii: 289645. doi: 10.1155/2010/289645
Brown LA, Kerr CJ, Whiting P, Finer N, McEneny J, Ash-ton T. Oxidant stress in healthy normal-weight, overweight and obese individuals. Obesity (Silver Spring). 2009; 17(3): 460- 466. doi: 10.1038/oby.2008.590
Esposito K, Ciotola M, Giugliano D. Oxidative stress in the metabolic syndrome. J Endocrinol Invest. 2006; 29: 791-795.
Hutley L, Prins JB. Fat as an endocrine organ: Relationship to the metabolic syndrome. Am J Med Sci. 2005; 330: 280-289. doi: 10.1097/00000441-200512000-00005
de Luca C, Scordo M, Cesareo E, et al. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic metaboliz-ing enzymes. Toxicol Appl Pharmacol. 2010; 248 (3): 285-292. doi: 10.1016/j.taap.2010.04.017
De Boer MD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: A need for screening tools to target interventions. Nutrition. 2013; 29(2): 379-386. doi: 10.1016/j.nut.2012.07.003
Hedley A, Ogden C, Johnson C, Carroll M, Curtin L, Flegal K. Prevalence of overweight and obesity among us children, ad-olescents, and adults, 1999-2002. JAMA. 2004; 291: 2847-2850. doi: 10.1001/jama.291.23.2847
Peairs AD, Abbey EL. Antioxidants and inflammation in obesity. In: Walson R, Preedy V, eds. Bioactive Food as Dietary Interventions for Diabetes. Boston, MA, USA: Academic Press; 2013: 413-434.
Aslan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese sub-jects. Pol Arch Med Wewn. 2011; 121: 181-186.
Fülö P, Harangi M, Seres I, Paragh G. Paraoxonase-1 and adipokines: Potential links between obesity and atherosclerosis. Chem Biol Interact. 2016; 259(Pt B): 388-393. doi: 10.1016/j. cbi.2016.04.003
Ndisang J, Mishra M. The heme oxygenase system selective-ly suppresses the proinflammatory macrophage M1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am J Hypertens. 2013; 26(9): 1123-1131. doi: 10.1093/ajh/ hpt082
Brigelius-Flohe R, Banning A, Kny M, Bol GF. Redox events in interleukin-1 signaling. Arch Biochem Biophys. 2004; 423: 66-73. doi: 10.1016/j.abb.2003.12.008
Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009; 1171: 59-76. doi: 10.1111/j.1749-6632.2009.04911.x
Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J. 1997; 11(2): 118-124.
Day C, Bailey C. Obesity in the pathogenesis of type 2 dia-betes. British Journal of Diabetes & Vascular Disease. 2011; 11(2): 55-61. doi: 10.1177/1474651411407418
Samuel V, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell. 2012; 148(5): 852- 871. doi: 10.1016/j.cell.2012.02.017
Schenk S, Saberi M, Olefsky J. Insulin sensitivity: Modu-lation by nutrients and inflammation. J Clin Investig. 2008; 118(9): 2992-3002. doi: 10.1172/JCI34260
White MF. Regulating insulin signaling and beta-cell func-tion through IRS proteins. Can J Physiol Pharmacol. 2006; 84: 725-737. doi: 10.1139/y06-008
Haus J, Kashyap S, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009; 58: 337- 343. doi: 10.2337/db08-1228
Muoio DM, Newgard CB. Mechanisms of disease: Molecu-lar and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9: 193- 205. doi: 10.1038/nrm2327
Nakajima K. Low serum amylase and obesity, diabetes and metabolic syndrome: A novel interpretation. World J Diabetes. 2016; 7(6): 112-121. doi: 10.4239/wjd.v7.i6.112
de Oliveira EP, Burini RC. High plasma uric acid concentra-tion: causes and consequences. Diabetol Metab Syndr. 2012; 4: 12. doi: 10.1186/1758-5996-4-12
Khitan Z, Kim DH. Fructose: A key factor in the develop-ment of metabolic syndrome and hypertension. J Nutr Metab. 2013; 2013: 682673. doi: 10.1155/2013/682673
Koek G, Liedorp P, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 2011; 412(15- 16): 1297-1305. doi: 10.1016/j.cca.2011.04.013
Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the meta-bolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007; 86(4): 899-906.
Karaouzene N, Merzouk H, Aribi M, et al. Effects of the association of aging and obesity on lipids, lipoproteins and oxidative stress biomarkers: A comparison of older with young men. Nutr Metab Cardiovasc Dis. 2011; 21(10): 792-799. doi: 10.1016/j.numecd.2010.02.007
Senior V, Marteau TM. Causal attributions for raised choles-terol and perceptions of effective risk-reduction: Self-regulation strategies for an increased risk of coronary heart disease. Psychol Health. 2007; 22: 699-717. doi: 10.1080/14768320601020253
Wu B, Fukuo K, Suzuki K, Yoshino G, Kazumi T. Rela-tionships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women. Endocr J. 2009; 56(6): 773-782. doi: 10.1507/endocrj. K08E-332
Verges B, Petit JM, Duvillard L, et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol. 2006; 26: 1364-1369. doi: 10.1161/01. ATV.0000219611.50066.bd
Dursun P, Demirtaþ E, Bayrak A, Yaralý H. Decreased serum paraoxonase 1 (PON1) activity: An additional risk factor for ath-erosclerotic heart disease in patients with PCOS? Hum Reprod. 2006; 21: 104-108. doi: 10.1093/humrep/dei284
Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular dis-ease. Prog Cardiovasc Dis. 2014; 56: 369-381. doi: 10.1016/j. pcad.2013.10.016
Mandviwala T, Khalid U, Deswa A. Obesity and cardiovas-cular disease: A risk factor or a risk marker? Curr Atheroscler Rep. 2016; 18: 21. doi: 10.1007/s11883-016-0575-4
Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart dis-ease, cardiovascular disease and all causes in United State adults. Circulation. 2004; 110: 1245-1250. doi: 10.1161/01. CIR.0000140677.20606.0E
Gharib M, Tao H, Fungwe T, Hajri T. Cluster differentiat-ing 36 (CD36) deficiency attenuates obesity-associated oxida-tive stress in the heart. PLoS One. 2016; 11(5): e0155611. doi: 10.1371/journal.pone.0155611
Hajri T, Hall AM, Jensen DR, et al. CD36-facilitated fatty acid uptake inhibits leptin production and signaling in adipose tissue. Diabetes. 2007; 56(7): 1872-1880. doi: 10.2337/db06- 1699
Juge-Aubry C, Henrichot E, Meier C. Adipose tissue: A reg-ulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005; 19(4): 547-566. doi: 10.1016/j.beem.2005.07.009
Hilzendeger AM, Morais RL, Todiras M, et al. Leptin regu-lates ACE activity in mice. J Mol Med. 2010; 88: 899-907. doi: 10.1007/s00109-010-0649-7
Chu KY, Leung PS. Angiotensin II in type 2 diabetes mel-litus. Curr Protein Pept Sci. 2009; 10: 75-84.
Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflamma-tory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 2009; 23: 265-276. doi: 10.1159/000218173
El-Bassossy H, El-Fawal R, Fahmy A, Watson M. Arginase inhibition alleviates hypertension in the metabolic syndrome. Br J Pharmacol. 2013; 169(3): 693-703. doi: 10.1111/bph.12144
Durante W, Peyton K, Liu X, et al. Arginase promotes en-dothelial dysfunction and Hypertension in obesity by restrict-ing Arginine bioavailability. FASEB J. 2015; 29(1): 805. doi: 10.1002/oby.20969
Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gas-troplasty. Int J Obes Relat Metab Disord. 1998; 22(3): 222-226.
Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005; 330: 326-335. doi: 10.1097/00000441-200512000-00011
De Abreu I, Guerra J, Pereira R, et al. Hypercholesterolemic diet induces hepatic steatosis and alterations in mRNA expres-sion of NADPH oxidase in rat livers. Arq Bras Endocrinol Me-tabol. 2014; 58(3): 251-259. doi: 10.1590/0004-2730000002831
Huang XD, Fan Y, Zhang H, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gas-troenterol. 2008; 14: 2888-2893. doi: 10.3748/wjg.14.2888
Mantena S, King A, Andringa K, Eccleston H, Bailey S. Mitochondrial dysfunction and oxidative stress in the pathogen-esis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008; 44(7): 1259-1272. doi: 10.1016/j.freerad-biomed.2007.12.029
Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficien-cy of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA. 2004; 101: 7281-7286. doi: 10.1073/pnas.0401516101
Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999; 274(42): 30028- 30032. doi: 10.1074/jbc.274.42.30028
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepa-tology. 2003; 37: 917-923. doi: 10.1053/jhep.2003.50161
Pike AF, Kramer NI, Blaauboer BJ, Seinen W, Brands R. A novel hypothesis for an alkaline phosphatase ‘rescue’ mecha-nism in the hepatic acute phase immune response. Biochim Biophys Acta. 2013; 1832: 2044-2056. doi: 10.1016/j.bbad-is.2013.07.016
Serra A, Romero R, López D, et al. Renal injury in the ex-tremely obese patients with normal renal function. Kidney Int. 2008; 73(8): 947-955. doi: 10.1038/sj.ki.5002796
D’Agati VD, Chagnac A, de Vries APJ, et al. Obesity-re-lated glomerulopathy: Clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016; 12: 453-471. doi: 10.1038/nrneph.2016.75
Wolf G, Chen S, Han D, Ziyadeh F. Leptin and renal dis-ease.Am J Kidney Dis. 2002; 39(1): 1-11. doi: 10.1053/ ajkd.2002.29865
Nakamura M, Satoh N, Suzuki M, et al. Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy. Biochem Biophys Res Com-mun. 2015; 461(1): 154-158. doi: 10.1016/j.bbrc.2015.04.005
Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney dis-ease: The Framingham Heart Study. Hypertension. 2011; 58(5): 784-790. doi: 10.1161/HYPERTENSIONAHA.111.175315
Hall JE, da Silva AA, do Carmo JM, et al. Obesity-induced hypertension: Role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010; 285: 17271-1726. doi: 10.1074/jbc.R110.113175
Hall JE, Brands MW, Zappe DH, et al. Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin-re-sistant dogs. Hypertension. 1995; 25: 994-1002. doi: 10.1161/01. HYP.25.5.994
Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 550-562. doi: 10.2215/ CJN.04071206
Trayhurn P, Wood IS. Signaling role of adipose tissue: Adi-pokines and inflammation in obesity. Biochem Soc Trans. 2005; 33(Pt 5): 1078-1081. doi: 10.1042/BST0331078
Sutherland JP, McKinley B, Eckel RH. The metabolic syn-drome and inflammation. Metab Syndr Relat Disord. 2004; 2: 82-104. doi: 10.1089/met.2004.2.82
Tilg H, Moschen AR. Inflammatory mechanisms in the regu-lation of insulin resistance. Mol Med. 2008; 14: 222-231. doi: 10.2119/2007-00119.Tilg
Wallace I, McKinley M, Bell P, Hunter S. Sex hormone bind-ing globulin and insulin resistance. Clin Endocrinol (Oxf). 2013; 78(3): 321-329. doi: 10.1111/cen.12086
Mukherjee S, Maitra A. Molecular & genetic factors contrib-uting to insulin resistance in polycystic ovary syndrome. Indian J Med Res. 2010; 131(6): 743-760.
Zuo T, Zhu M, XuW. Roles of oxidative stress in polycys-tic ovary syndrome and cancers. Oxid Med Cell Longev. 2015; 2016: 8589318. doi: 10.1155/2016/8589318
Seow KM, Juan CC, WuLY, et al. Serum and adipocyte re-sistin in polycystic ovary syndrome with insulin resistance. Hum Reprod. 2004; 19(1): 48-53. doi: 10.1016/j.ejogrb.2010.08.022
He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes. 2001; 50(4): 817-823. doi: 10.2337/diabetes.50.4.817
Hulver M, Berggren J, Cortright R, et al. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab. 2003; 284(4): E741-E747. doi: 10.1152/ajpendo.00514.2002
Friedman J, Caro J, Pories W, Azevedo J, Dohm G. Glu-cose metabolism in incubated human muscle: Effect of obesity and non-insulin-dependent diabetes mellitus. Metabolism. 1994; 43(8): 1047-1054. doi: 10.1016/0026-0495(94)90188-0
Carvalho-Filho MA, Ueno M, Hirabara SM, et al. S-nitro-sation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: A novel mechanism of insulin resistance. Diabetes. 2005; 54: 959-967. doi: 10.2337/diabetes.54.4.959
Brehm A, Krssak M, Schmid AI, Nowotny P, Waldhäusl W, Roden M. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes. 2006; 55: 136-140. doi: 10.2337/diabetes.55.01.06.db05-1286
Robling AG, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng. 2006; 8: 455-498.
Hsu YH, Venners SA, Terwedow HA, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr. 2006;83(1): 146-154.
Bronsky J, Prusa R, Nevoral J. The role of amylin and related peptides in osteoporosis. Clin Chim Acta. 2006; 373: 9-16. doi: 10.1016/j.cca.2006.05.009
Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY. Re-lationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical mark-ers in Chinese men. Clin Chim Acta. 2008; 387: 31-35. doi: 10.1016/j.cca.2007.08.012
Shapses SA, Riedt CS. Bone, body weight, and weight re-duction: What are the concerns? J Nutr. 2006; 136:1453-1456.
Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM. Expression and functional consequences of 11 be-ta-hydroxysteroid dehydrogenase activity in human bone. Bone. 2000; 27(3): 375-381. doi: 10.1016/S8756-3282(00)00344-6
Sinha N, Shieh A, Stein EM, et al. Increased PTH and 1.25(OH)(2)D levels associated with increased markers of bone turnover following bariatric surgery. Obesity (Silver Spring). 2011; 19(12): 2388-2393. doi: 10.1038/oby.2011.133
Al-Aubaidy H, Jelinek H. Oxidative DNA damage and obe-sity in type 2 diabetes mellitus. Eur J Endocrinol. 2011; 164: 899-904. doi: 10.1530/EJE-11-0053
Vucenik I, Stains J. Obesity and cancer risk: Evidence, mechanisms, and recommendations. Ann N Y Acad Sci. 2012; 12(71): 37-43. doi: 10.1111/j.1749-6632.2012.06750.x
Calle E, Rodriguez C, Walker-Thurmond K, Thun M. Over-weight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med. 2003; 348: 1625- 1638. doi: 10.1056/NEJMoa021423
Ortega R, Rodríguez-Rodríguez E, Aparicio A, et al. Young children with excess of weight show an impaired selenium sta-tus. Int J Vitam Nutr Res. 2012; 82: 121-129. doi: 10.1024/0300- 9831/a000101
Weisstaub G, Hertrampf E, López de Romaña D, Salazar G, Bugueño C, Castillo-Duran C. Plasma zinc concentration, body composition and physical activity in obese preschool children. Biol Trace Elem Res. 2007; 118: 167-174. doi: 10.1007/s12011- 007-0026-8
Hermsdorff H, Puchau B, Volp A, et al. Dietary total anti-oxidant capacity is inversely related to central adiposity as well as to metabolic and oxidative stress markers in healthy young adults. Nutr Metab. 2011; 22: 8-59. doi: 10.1186/1743-7075-8-
Del Rio D, Agnoli C, Pellegrini N, et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr. 2011; 141: 118-123. doi: 10.3945/jn.110.125120
Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic dis-eases. Exp Biol Med. 2008; 233(6): 674-688. doi: 10.3181/0711- MR-311
Arunkumar E, Bhuvaneswari S, Anuradha C. An intervention study in obese mice with astaxanthin, a marine carotenoid—Ef-fects on insulin signaling and pro-inflammatory cytokines. Food Funct. 2012; 3: 120-126. doi: 10.1039/c1fo10161g
Song Y, Xu Q, Park Y, Hollenbeck A, Schatzkin A, Chen H. Multivitamins, individual vitamin and mineral supplements, and risk of diabetes among older U.S. adults. Diabetes Care. 2011; 34: 108-114. doi: 10.2337/dc10-1260
Leiherer A, Mündlein A, Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul. Pharmacol. 2013; 58: 3-20. doi: 10.1016/j.vph.2012.09.002
Pedret A, Valls R, Fernández-Castillejo S, et al. Polyphe-nol-rich foods exhibit DNA antioxidative properties and protect the glutathione system in healthy subjects. Mol Nutr Food Res. 2012; 56: 1025-1033. doi: 10.1002/mnfr.201100676
Siriwardhana N, Kalupahana N, Cekanova M, Lemieux M, Greer B, Moustaid-Moussa N. Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem. 2013; 24: 613-623. doi: 10.1016/j.jnutbio.2012.12.013
Sies H, Hollman P, Grune T, Stahl W, Biesalski H, Williamson G. Protection by flavanol-rich foods against vascular dysfunc-tion and oxidative damage: 27th Hohenheim Consensus Confer-ence. Adv Nutr. 2012; 3: 217-221. doi: 10.3945/ an.111.001578
Tan B, Li X, Yin Y, et al. Regulatory roles for l-arginine in re-ducing white adipose tissue. Front Biosci. 2012; 17: 2237-2246.
Zemel M, Bruckbauer A. Effects of a leucine and pyridox-ine-containing nutraceutical on fat oxidation, and oxidative and inflammatory stress in overweight and obese subjects. Nutrients. 2012; 4: 529-541. doi: 10.3390/nu4060529
Crujeiras AB, Parra MD, Rodríguez MC, Martínez de Moren-tin BE, Martínez JA. A role for fruit content in energy-restricted diets in improving antioxidant status in obese women during weight loss. Nutrition. 2006; 22(6): 593-599. doi: 10.1016/j. nut.2006.03.008
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Obesity Research (OR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
